



Schwarz Pharma's KUDCo Not Seeking to Temporarily Halt Mylan's Omeprazole Sales

PITTSBURGH--(BUSINESS WIRE)--Aug. 8, 2003--Contrary to the implications in Schwarz Pharma's August 7, 2003 press release, and after consultation with KUDCo's attorneys, Mylan Laboratories Inc. (NYSE: MYL) today confirms that KUDCo is not seeking to temporarily halt Mylan's sales of generic omeprazole capsules.

Mylan initiated litigation against KUDCo in November 2002, alleging that KUDCo's sale of omeprazole infringed Mylan's patent. Mylan has also sought permission to sue Dr. Pawan Seth, alleging improper conduct in providing KUDCo with the product it is selling. Having failed to file any compulsory counterclaim in that suit by the court's July 18, 2003 deadline, KUDCo has now brought suit in an apparent attempt to bring the counterclaims not properly filed in the pending suit.

According to Mylan's Vice Chairman and CEO Robert J. Coury: "We view Schwarz Pharma's tactics as simply a desperate effort both to correct its problems in the pending litigation and to inflict confusion on the buying market and the investing public. Mylan does not intend to engage in any rhetoric campaign but instead will focus on the legal merits of the case."

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary prescription products. For more information about Mylan, visit www.mylan.com.

This press release includes statements that constitute "forward-looking statements", including with regard to Mylan's sale of omeprazole capsules and the merits of pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties regarding the unresolved patent infringement allegations against the Company, including the possibility that the patent holder may seek, and may be granted, injunctive relief or money damages; uncertainties and risks in other pending litigation matters; the possible negative effects of any interruption of manufacturing of the omeprazole capsules at the Company's facility; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

CONTACT: Mylan Laboratories Inc., Canonsburg
Kris King, 724-514-1800

SOURCE: Mylan Laboratories Inc.